AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

1 month ago 7

Trey Thoelcke

Wed, July 15, 2026 astatine 6:45 AM CDT 5 min read

Quick Read

AbbVie's aureate transverse is widening with a 2.8% dividend yield, portion Baxter's razor-thin transverse sits atop a still-declining 200-day moving average.
Baxter eliminated its dividend and posted -$900 cardinal nett income successful FY2025, disqualifying it for immoderate income-focused status portfolio.
Skyrizi and Rinvoq grew 31% and 23% successful Q1 2026, much than offsetting Humira's biosimilar losses and driving AbbVie's full-year guidance raise.
This lithium shaper surpassed a $1B backstage valuation, joining immoderate of America's astir almighty startups. Now you tin invest successful EnergyX alongside planetary giants similar General Motors, but lone done July 16. (sponsor)

Both AbbVie (NYSE:ABBV) and Baxter International (NYSE:BAX) flashed the aforesaid method awesome this month: a aureate cross, wherever the 50-day moving mean pushed supra the 200-day. The status question is simple: which 1 belongs successful an income-focused portfolio close now?

A four-part illustration comparing a sunny, prosperous status with rising banal charts to a gloomy, rocky scenery with falling charts and bare wallets.

AbbVie's cross, formed astir July 7, is cleanable and widening: the 50-day is 222.91 versus a 200-day of 222.66, with some lines rising. Baxter's transverse is simply a antithetic picture. The 50-day astatine 19.85 is lone fractionally supra a 200-day astatine 19.26, and the 200-day is inactive declining. Remember that aureate crosses are lagging momentum indicators. They accidental thing astir currency travel oregon dividend safety. So the verdict has to travel from fundamentals.

Dimension 1: Dividend Durability and Yield

AbbVie conscionable declared its $1.73 quarterly payout, with an ex-dividend day of July 15, 2026, and outgo connected August 14, 2026. That annualizes to $6.92, extending a 13-year streak of increases dating to the 2013 Abbott spinoff, with the astir caller hike a 5.5% bump. At the existent terms of $244.78, that represents a output adjacent 2.8%.

Baxter is the other story. Management slashed the quarterly dividend to $0.01 alongside Q4 2025 results, efficaciously eliminating the payout. Annualized, that is $0.04 per share.

The victor is AbbVie, decisively. Retirees penning checks from portfolio income cannot usage a token dividend.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ mundane investors person already backed lithium shaper EnergyX.

Here's wherefore you should bash the aforesaid earlier their July 16 concern deadline: lithium prices are up 75% this year, with request projected to turn a staggering 5X by 2040.

With tech that tin retrieve up to 3X much lithium than accepted methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX capitalist earlier the July 16 deadline.

Read Entire Article